Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives
In today`s therapy of type 2 diabetes mellitus, SGLT2 inhibitors have taken their rightful place both due to their positive hypoglycemic and outstanding cardiorenometabolic effects. Recent randomized clinical trials, such as DAPA HF, EMPEROR-Reduced and EMPEROR-Preserved, show the benefits of their...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2022-07-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12855 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850140859808350208 |
|---|---|
| author | V. V. Salukhov G. R. Galstyan T. A. Ilyinskay |
| author_facet | V. V. Salukhov G. R. Galstyan T. A. Ilyinskay |
| author_sort | V. V. Salukhov |
| collection | DOAJ |
| description | In today`s therapy of type 2 diabetes mellitus, SGLT2 inhibitors have taken their rightful place both due to their positive hypoglycemic and outstanding cardiorenometabolic effects. Recent randomized clinical trials, such as DAPA HF, EMPEROR-Reduced and EMPEROR-Preserved, show the benefits of their use in the treatment of patients with chronic heart failure without regard to the status of type 2 diabetes mellitus and so significantly expands the range of use of SGLT2 in the practice of doctors of various specialties. This review presents not only the results of the most significant studies of SGLT2 inhibitors, but also the main approaches to the starting therapy with this class of drugs in various clinical situations, both inpatient and outpatient. In addition, potential adverse events and limitations associated with the use of SGLT2 inhibitors are discussed in detail, which must be taken into account when prescribing in particular patient. The practical aspects of SGLT2 inhibitors` prescription are considered separately through the prism of their safe use in the perioperative and postinfarction periods, as well as during other special conditions. Particular attention is paid to the monitoring of physical and general examination data and laboratory instrumental tests, the consideration of which will minimize adverse events and best benefit for many cardiological, endocrinological and nephrological patients. |
| format | Article |
| id | doaj-art-b469470307cc43c18b66115371c81a69 |
| institution | OA Journals |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-b469470307cc43c18b66115371c81a692025-08-20T02:29:39ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782022-07-0125327528710.14341/DM1285510956Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectivesV. V. Salukhov0G. R. Galstyan1T. A. Ilyinskay2S.M. Kirov Military Medical AcademyEndocrinology Research CentreS.M. Kirov Military Medical AcademyIn today`s therapy of type 2 diabetes mellitus, SGLT2 inhibitors have taken their rightful place both due to their positive hypoglycemic and outstanding cardiorenometabolic effects. Recent randomized clinical trials, such as DAPA HF, EMPEROR-Reduced and EMPEROR-Preserved, show the benefits of their use in the treatment of patients with chronic heart failure without regard to the status of type 2 diabetes mellitus and so significantly expands the range of use of SGLT2 in the practice of doctors of various specialties. This review presents not only the results of the most significant studies of SGLT2 inhibitors, but also the main approaches to the starting therapy with this class of drugs in various clinical situations, both inpatient and outpatient. In addition, potential adverse events and limitations associated with the use of SGLT2 inhibitors are discussed in detail, which must be taken into account when prescribing in particular patient. The practical aspects of SGLT2 inhibitors` prescription are considered separately through the prism of their safe use in the perioperative and postinfarction periods, as well as during other special conditions. Particular attention is paid to the monitoring of physical and general examination data and laboratory instrumental tests, the consideration of which will minimize adverse events and best benefit for many cardiological, endocrinological and nephrological patients.https://www.dia-endojournals.ru/jour/article/view/12855type 2 diabetes mellituschronic heart failuresglt2 inhibitoradverse eventssafety, initiation of inpatient treatment |
| spellingShingle | V. V. Salukhov G. R. Galstyan T. A. Ilyinskay Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives Сахарный диабет type 2 diabetes mellitus chronic heart failure sglt2 inhibitor adverse events safety, initiation of inpatient treatment |
| title | Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives |
| title_full | Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives |
| title_fullStr | Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives |
| title_full_unstemmed | Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives |
| title_short | Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives |
| title_sort | practical aspects of initiation and use of sglt2 inhibitors inpatient and outpatient perspectives |
| topic | type 2 diabetes mellitus chronic heart failure sglt2 inhibitor adverse events safety, initiation of inpatient treatment |
| url | https://www.dia-endojournals.ru/jour/article/view/12855 |
| work_keys_str_mv | AT vvsalukhov practicalaspectsofinitiationanduseofsglt2inhibitorsinpatientandoutpatientperspectives AT grgalstyan practicalaspectsofinitiationanduseofsglt2inhibitorsinpatientandoutpatientperspectives AT tailyinskay practicalaspectsofinitiationanduseofsglt2inhibitorsinpatientandoutpatientperspectives |